Human Germline Genome Editing

摘要: With CRISPR/Cas9 and other genome-editing technologies, successful somatic germline genome editing are becoming feasible. To respond, an American Society of Human Genetics (ASHG) workgroup developed this position statement, which was approved by the ASHG Board in March 2017. The included representatives from UK Association Genetic Nurses Counsellors, Canadian International Epidemiology Society, US National Counselors. These groups, as well for Reproductive Medicine, Asia Pacific Genetics, British Australasia, Professional Counselors Asia, Southern African endorsed final statement. statement includes following positions. (1) At time, given nature number unanswered scientific, ethical, policy questions, it is inappropriate to perform gene that culminates human pregnancy. (2) Currently, there no reason prohibit in vitro on embryos gametes, with appropriate oversight consent donors, facilitate research possible future clinical applications editing. There should be prohibition making public funds available support research. (3) Future application not proceed unless, at a minimum, (a) compelling medical rationale, (b) evidence base supports its use, (c) ethical justification, (d) transparent process solicit incorporate stakeholder input.